Omabit is an artificial intelligence startup headquartered in San Francisco, California, that helps scientists perform genomics data analysis. It operates in the biotechnology research sector.
Subscribe to see Omabit’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Omabit is a healthcare company headquartered in San Francisco, United States. Its most recent funding round, Seed, raised $2M in October 2026.
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Omabit's closest competitors — see the full list of competitors and alternatives →
Novaflow is an early-stage artificial intelligence startup backed by Y Combinator (YC S25) that operates as an AI data analyst. Based in San Francisco, California, the company provides automated data analysis tools for businesses.
WhiteLab Genomics is a biotechnology research company headquartered in Paris, France, founded in 2019. Backed by Y-Combinator, the company pioneers artificial intelligence solutions to accelerate the development of genomic medicines and life-science applications.
OneThree Biotech, Inc. is a New York City-based biotechnology company founded in 2018. The company develops an artificial intelligence-driven discovery platform designed to accelerate drug discovery and development by predicting novel targets, identifying patient-specific biomarkers, and finding drug candidates for repurposing.
DeepSeq.AI is a biotechnology research company headquartered in California that builds protein interaction databases and utilizes artificial intelligence for drug discovery.
Noetik Inc. is an AI-native biotechnology company headquartered in South San Francisco, California, leveraging advanced machine learning methods for biological discovery.
GATC Health Corp. is a biotechnology company that uses artificial intelligence, genomics, and toxicology data to discover and develop therapeutics and predict drug safety. Its work is aimed at pharmaceutical and biotechnology partners as well as patients needing treatments for serious diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Omabit? Suggest a correction · Work at Omabit? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.